AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 171 min read$MNKD

Thomson David sold $98K of MNKD

Thomson David (EVP Genl Counsel & Secretary) sold 24,109 shares of MANNKIND CORP (MNKD) at $4.05 on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomson David
Published Jul 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale details (shares, price, total value) by an executive under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental information beyond confirming the transaction occurred.

03

What to watch

Traders may over-weight insider selling; without accompanying buy/sell patterns, guidance, or operational updates, the signal is weak.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-17 (same day as transaction)

Background

The article is a primary-source SEC Form 4 insider transaction for MannKind Corp (MNKD).

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind disclosed an EVP general counsel and secretary open-market sale of 24,109 shares at $4.05 on 2026-07-17 under a 10b5-1 plan.

Expected impact

Likely minimal, though it can add short-term overhang if traders interpret it as bearish.

Evidence & confidence

Form 4 insider sales are common and the article specifies a pre-arranged 10b5-1 plan, which reduces the likelihood of information asymmetry. The disclosed size is moderate relative to typical large-cap flows, and no other MNKD-specific catalyst is provided.

Market effects

Sector

No sector-level implications; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than a view on MNKD prospects.

Key entities

  • issuer
    MANNKIND CORP

    US-listed company whose Form 4 insider sale was disclosed.

  • insider
    Thomson David

    EVP, General Counsel and Secretary who sold shares.

Read at source← All news

Related articles

AUG 5
$MNKDMedAI 8/10

MANNKIND CORP (MNKD): Results of Operations and Financial Condition

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ aut

SEC EDGAR 8-K4 min
JUL 29
$MNKDMed

MannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients

MannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.

rttnews.com4 min
JUL 29
$MNKDMedAI 8/10

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.

finanznachrichten.de3 min
JUL 24
$MNKDMedAI 8/10

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M

The FDA approved MannKind’s Furoscix ReadyFlow, a furosemide injection autoinjector for edema in adults with heart failure or chronic kidney disease. MannKind said it delivers an 80 mg/mL dose in under 10 seconds. The company also announced a private placement of about $50 million to fund general purposes, including a $45 million contingent value rights payment. MNKD shares rose to about $4.16.

benzinga.com4 min